What lifestyle modifications are most effective at reducing liver fat in MASLD, and how soon can improvement be seen?

Weight loss of 7–10 % of body weight through a Mediterranean‑style diet, reduced added sugars, and at least 150 minutes of moderate‑intensity exercise per week can lower hepatic fat by 30–50 % within 3–6 months; regular monitoring of ALT/AST helps track response.

How do clinicians differentiate MASLD from alcoholic fatty liver disease on imaging and laboratory studies?

Both show hepatic steatosis on ultrasound or MRI, but MASLD is diagnosed when alcohol intake is ≤ 21 g/day for men or ≤ 14 g/day for women, and when metabolic risk factors (obesity, diabetes, dyslipidemia, hypertension) are present; serum gamma‑glutamyl transferase may be higher in alcoholic disease, and a detailed alcohol history is essential.

When is a liver biopsy indicated for a patient with MASLD?

Biopsy is reserved for cases where non‑invasive scores (FibroScan, ELF) suggest advanced fibrosis (≥ F3), when the diagnosis is uncertain (e.g., atypical lab pattern), or when other liver diseases need to be ruled out before initiating pharmacotherapy.

What pharmacologic treatments are currently approved or in late‑stage trials for MASLD, and who qualifies for them?

s of 2024, the GLP‑1 receptor agonist semaglutide is approved for MASLD with fibrosis stage F2‑F3 in patients with type 2 diabetes or obesity; other agents such as obeticholic acid and resmetirom are in phase III trials and may be offered via clinical trials to patients with biopsy‑proven NASH and fibrosis.

Metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition characterized by fat buildup in the liver, affecting approximately 25 percent of adults worldwide and posing significant risks for liver damage and cardiovascular disease.

Overview

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition characterized by a buildup of fat in the liver, which can lead to liver damage. The liver is part of the digestive system and helps break down food, store energy, and remove waste products. If more than 5 percent of the liver contains fat, the liver is considered to be fatty (steatotic).

MASLD is most common among middle-aged or older people, although younger people, including children, may also be affected. People with MASLD have liver steatosis along with at least one of the following features:

Higher body weight
Type 2 diabetes
One of several metabolic abnormalities, including:
- Pre-diabetes (insulin resistance)
- High levels of fats (lipids) such as triglycerides in the blood
- High blood pressure (hypertension)

MASLD is estimated to occur in up to 75 percent of adults with obesity or high levels of lipids in the blood and in up to 65 percent of adults with type 2 diabetes. In people with MASLD, the liver problems are not caused by alcohol use disorder.

Symptoms

In people with MASLD, the fat deposits in the liver can cause increased levels of liver enzymes that can be detected during routine blood tests. Some affected individuals experience:

Abdominal pain
Fatigue

During a physical examination, the liver may be found to be slightly enlarged.

Causes & Risk Factors

The specific causes of MASLD are unclear, although this condition is likely a result of both environmental factors and changes in several genes. Genetic changes that increase the risk of disease are called pathogenic variants.

Dietary and Environmental Factors

When the amount of fat in a person's diet exceeds the amount the body can use, some of the fat is stored in the liver. Researchers suggest that a diet that is high in cholesterol, the refined sugars used in processed foods, and certain other nutrients may increase the likelihood of developing MASLD.

Progression to MASH and Cirrhosis

It is unclear what causes metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis to develop in some people with MASLD. Researchers are studying several possible mechanisms, including:

Inflammation caused by an immune system reaction to the buildup of fat in the liver
Toxic inflammatory chemicals (cytokines) released by the liver cells or fat cells
The self-destruction of liver cells
The effect of unstable molecules called free radicals (oxidative stress)
The role of different populations of microorganisms in the intestines (gut microbiota)

Genetic Factors

Studies have identified many genetic changes that may be associated with the development of MASLD and MASH. Among these is a particular variant in the PNPLA3 gene. This gene provides instructions for making an enzyme that is found in fat and liver cells. The PNPLA3 enzyme likely helps process and store fats from the diet. The PNPLA3 gene variant that is associated with MASLD is thought to cause cells to produce an altered version of the enzyme that increases fat retention and decreases breakdown of fats in the liver. Genetic variants seem to only play a small role in the development of MASLD. Ongoing research will show how additional genetic changes contribute to the development of MASLD and its complications.

Other genes associated with this condition include:

APOC3
GCKR
MBOAT7
TM6SF2
TRIB1

Frequency

MASLD occurs in about 25 percent of adults and 7 to 14 percent of children worldwide. It is the most common chronic liver disorder in Western countries, including the United States, and its prevalence is increasing along with the rising prevalence of obesity. It is estimated that MASLD will affect over half of individuals by 2040.

Complications & Prognosis

MASLD is slow to worsen, or it may not worsen at all. In many affected individuals, the buildup of fat in the liver can be reduced by adopting healthy habits. However, up to 30 percent of people with MASLD develop inflammation of the liver (MASH), which can damage the liver.

In people with long-term liver damage, normal liver tissue may be replaced with scar tissue (fibrosis), resulting in permanent liver disease (cirrhosis) and, eventually, liver failure. People with MASLD, MASH, and cirrhosis have a higher risk of developing liver cancer (hepatocellular cancer). People with MASLD are also at increased risk of developing additional health problems such as heart (cardiovascular) disease.

Inheritance

An increased risk of developing MASLD can be passed down through generations in families, but the inheritance pattern is unknown.

Other Names for This Condition

MASLD
NAFLD
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis